TP53 and non-small cell lung carcinoma: First, analysis of large public datasets indicates that levels of AURKA are comparable or higher in KRASmut versus EGFRmut NSCLC, with highest levels in tumors with mutated TP53; and levels of EGFR that are appreciable although lower are expressed in KRASmut NSCLC tumors.